Skip to content
value.today
Evotec SE logo

Evotec SE

EVT.DE
$720 Mmarket cap on Aug 1, 2026-78.8% since Jan 2024
Compare
World rank
#10,960
Revenue
$862 M
For year ending December-2024
Net income
$-212 M
-24.6% margin
SEC filing
Employees
4,952
As on 2022
value.today research

Evotec SE in brief

Evotec SE is a listed company in the Pharmaceutical industry, based in Germany. It was founded in 1993. Its market value was $720 M on 1 August 2026, which makes it the 10,960th largest listed company in the world and the 173rd largest in Germany on this site. In the year to December 2024 it had sales of $862 M and a net loss of $212 M. It employs about 4,952 people. Its largest product and service lines by sales in 2025 were Fee for service and FTE-based research services (78%), Licences (16%) and Material re-charges to customers (4%). By market, the largest shares of its 2025 sales came from USA (55%), Switzerland (20%) and UK (8%). Its shares trade under the symbol EVT.DE (Deutsche Borse).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Evotec SE

Evotec is a drug discovery alliance and development partnership company focused on innovative product approaches with leading pharmaceutical and biotechnology companies, academics, patient advocacy groups. Headquarters is in Germany.

As on 2020, Evotec has 3,030 employees across 14 countries.

Evotec has long-term discovery alliances with partners including Bayer, Boehringer Ingelheim, Bristol Myers Squibb, CHDI, Novartis, Novo Nordisk, Pfizer, Sanofi, Takeda, UCB.

Evotec SE timeline

2 events, 1993–2014
  1. 1993
  2. 🏁
    · approximate
    Founded by Manfred Eigen
  3. 2014
  4. •
    Legal Entity Identifier issued
    LEI 529900F9KI6OYITO9B12 registered.

Events of Evotec SE from Wikidata and the GLEIF LEI register. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$2.0 B$4.0 B$6.0 B$8.0 B2020202120222023202420252026

World rank over time

▼ down 7,599 places since 2020
2020-01-01: #3193#3,19320202021-01-01: #2533#2,53320212022-01-07: #2406#2,40620222022-12-25: #4226#4,22620222023-07-30: #3264#3,26420232024-01-05: #3987#3,98720242026-08-01: #10792#10,7922026

Rank in Germany: #93 (Jan 2020) · #83 (Jan 2021) · #72 (Jan 2022) · #93 (Dec 2022) · #74 (Jul 2023) · #85 (Jan 2024) · #175 (Aug 2026)

Key ratios

market cap and latest results · TTM = trailing 12 months
P/E ratio (TTM)
n/m (loss)
Price / sales (TTM)
0.8×
Price / book
0.7×
Free cash flow yield
-14.9%
Net margin (TTM)
-24.6%
Operating margin
-17.9%
Return on equity
-21.4%
Liabilities / assets
50.2%
Net debt
$-93M
Revenue growth
+2.1%
R&D / revenue
6.4%
Revenue per employee
$174 K
Profit per employee
$-43 K

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2019: revenue $500M, net income $43M$500MFY19Fiscal year ending Dec 2020: revenue $571M, net income $7M$571MFY20Fiscal year ending Dec 2021: revenue $731M, net income $255M$731MFY21Fiscal year ending Dec 2022: revenue $790M, net income $-185M$790MFY22Fiscal year ending Dec 2023: revenue $845M, net income $-91M$845MFY23Fiscal year ending Dec 2024: revenue $862M, net income $-212M$862MFY24
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2024$862M+2.1%$-154M$-212M-24.6%
Dec 2023$845M+7.0%$-51M$-91M-10.7%
Dec 2022$790M+8.1%$22M$-185M-23.4%
Dec 2021$731M+27.9%$48M$255M34.9%
Dec 2020$571M+14.3%$55M$7M1.3%
Dec 2019$500M—$70M$43M8.5%

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2024$20M$127M$-107M$-1.20—
Dec 2023$39M$231M$-191M$-0.51—
Dec 2022$216M$191M$26M$-1.04—
Dec 2021$150M$141M$9M$1.54—
Dec 2020$51M$113M$-62M$0.05—
Dec 2019$47M$35M$12M$0.28—

SEC filings

Official filings of Evotec SE with the US Securities and Exchange Commission.

Annual results

Revenue
$862 M
Operating income
$-154 M
Net income
$-212 M

For year ending December-2024 · source: SEC filing

Balance sheet

Total assets
$2.0 B
Total liabilities
$997 M
Total equity
$990 M

As of December-2024

EVOTEC SE - Yearly Revenue and Net Income - in Million EUR

Year - EndingRevenueOperating IncomeNet Income
Dec-202275120-175 (Loss)
Dec-2021618 41215
Dec-2020500 516
Dec-20194467438
Dec-20183756284

Balance sheet

Total Assets as on Dec-2022 was 2,257 Million EUR.

Total Liabilities as on Dec-2022 was 1,070 Million EUR.

Total Equity as on Dec-2022 was 1,187 Million EUR.

Top 25 institutional investors in Evotec SE#

As of Sep 30, 2026
25 institutions held 1.9 M shares (about 0.5% of the shares outstanding) on Sep 30, 2026. The ten largest hold 0.5%. Source: SEC Form 13F filings, filed through Nov 17, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 25 largest institutional investors in Evotec SE
#InstitutionShares heldChange (shares)% heldValueFiled
1DCF Advisers, LLC1,048,362-30,662 (-2.84%)0.29%$2 MNov 4, 2026
2Abc Arbitrage SA541,106+169,170 (+45.48%)0.15%$1 MOct 23, 2026
3Optiver Holding B.V.62,562-259,591 (-80.58%)0.02%$0 MNov 16, 2026
4Fore Capital, LLC51,355+20,000 (+63.79%)0.01%$0 MNov 13, 2026
5Morgan Stanley32,545-173,218 (-84.18%)0.01%$0 MNov 13, 2026
6Millennium Management LLC26,517+3,684 (+16.13%)0.01%$0 MNov 16, 2026
7SmartHarvest Portfolios, LLC25,173New0.01%$0 MOct 26, 2026
8Old Mission Capital LLC22,948-15,084 (-39.66%)0.01%$0 MNov 16, 2026
9XTX Topco Ltd21,688+3,797 (+21.22%)0.01%$0 MNov 16, 2026
10Squarepoint Ops LLC20,480New0.01%$0 MNov 9, 2026
11HRT Financial LP18,763New0.01%$0 MNov 13, 2026
12BNP Paribas Financial Markets15,900+2,623 (+19.76%)0.00%$0 MNov 12, 2026
13Virtu Financial LLC12,944New0.00%$0 MNov 17, 2026
14CSS Llc/il12,1000 (0.00%)0.00%$0 MNov 16, 2026
15Geode Capital Management, LLC11,2720 (0.00%)0.00%$0 MNov 6, 2026
16Vanguard Personalized Indexing Management, LLC10,370-3,226 (-23.73%)0.00%$0 MNov 16, 2026
17UBS Group AG1,815New0.00%$0 MNov 10, 2026
18Rockefeller Capital Management L.P.704-9,515 (-93.11%)0.00%$0 MNov 13, 2026
19Osaic Holdings, Inc.310-30 (-8.82%)0.00%$0 MNov 12, 2026
20Jpmorgan Chase & Co1000 (0.00%)0.00%$0 MNov 12, 2026
21SBI Securities Co., Ltd.97+2 (+2.11%)0.00%$0 MOct 22, 2026
22Farther Finance Advisors, LLC97+80 (+470.59%)0.00%$0 MOct 8, 2026
23Strive Financial Group ,LLC410 (0.00%)0.00%$0 MNov 9, 2026
24Silver Grove Financial Group, Inc.250 (0.00%)0.00%$0 MNov 5, 2026
25Caitong International Asset Management Co., Ltd19+16 (+533.33%)0.00%$0 MOct 29, 2026

Mutual funds holding Evotec SE#

49 funds in 2 countries hold shares worth $78 M (about 8.8% of the company). Since their previous reports 17 added shares and 12 sold, selling $4 M net. By country: USA 48 ($78 M), Sweden 1 ($0 M).
Mutual funds holding Evotec SE
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 First Trust WCM International Equity ETFFirst Trust Advisors L.P.2.60 M$15 M1.4%0.90%+33%Jun 30, 2026
🇺🇸 Brown Capital Management International Small Company FundBrown Capital Management, LLC2.00 M$11 M1.1%1.7%−48%Jun 30, 2026
🇺🇸 Vanguard Total International Stock Index FundThe Vanguard Group, Inc.2.32 M$9 M1.3%<0.01%no changeJul 31, 2026
🇺🇸 Vanguard Developed Markets Index FundThe Vanguard Group, Inc.1.55 M$9 M0.85%<0.01%no changeJun 30, 2026
🇺🇸 iShares Core MSCI EAFE ETFBlackRock Fund Advisors1.09 M$4 M0.60%<0.01%+1.2%Jul 31, 2026
🇺🇸 JNL Multi-Manager International Equity FundJackson National Asset Management, LLC530,535$3 M0.29%0.21%newJun 30, 2026
🇺🇸 Vanguard Ftse All-World Ex-Us Small-Cap Index FundThe Vanguard Group, Inc.660,978$3 M0.36%0.02%+7.9%Jul 31, 2026
🇺🇸 Schwab International Small-Cap Equity ETFCharles Schwab Investment Management, Inc.339,204$2 M0.19%0.04%+11%May 31, 2026
🇺🇸 iShares MSCI EAFE Small-Cap ETFBlackRock Fund Advisors486,587$2 M0.27%0.01%−13%Jul 31, 2026
🇺🇸 Dfa International Small Cap Value PortfolioDimensional Fund Advisors LP477,830$2 M0.26%0.01%no changeJul 31, 2026
🇺🇸 WCM Focused International Equity FundWCM Investment Management, LLC320,000$2 M0.17%0.73%—Jun 30, 2026
🇺🇸 International Core Equity 2 PortfolioDimensional Fund Advisors LP414,281$2 M0.23%<0.01%no changeJul 31, 2026
🇺🇸 Vanguard European Stock Index FundThe Vanguard Group, Inc.374,933$1 M0.20%<0.01%−2.9%Jul 31, 2026
🇺🇸 First American Multi-Manager International Equity FundU.S. Bancorp Asset Management, Inc.234,816$1 M0.13%0.14%−7.4%Jun 30, 2026
🇺🇸 Dimensional International Small Cap Value ETFDimensional Fund Advisors LP340,378$1 M0.19%0.03%no changeJul 31, 2026
🇺🇸 Diamond Hill International FundDiamond Hill Capital Management, Inc.215,817$1 M0.12%0.72%no changeJun 30, 2026
🇺🇸 iShares Core MSCI Total International Stock ETFBlackRock Fund Advisors250,538$1 M0.14%<0.01%+1.4%Jul 31, 2026
🇺🇸 Dimensional International Small Cap ETFDimensional Fund Advisors LP247,236$1 M0.14%0.02%+6.5%Jul 31, 2026
🇺🇸 iShares Core MSCI International Developed Markets ETFBlackRock Fund Advisors236,942$1 M0.13%<0.01%+4.7%Jul 31, 2026
🇺🇸 State Street SPDR Portfolio Developed World ex-US ETFSSGA Funds Management, Inc.139,716$1 M0.08%<0.01%−0.1%Jun 30, 2026
🇺🇸 College Retirement Equities Fund - Total Global Stock AccountTIAA-CREF Investment Management, LLC99,443$1 M0.05%<0.01%no changeJun 30, 2026
🇺🇸 Dimensional International Core Equity 2 ETFDimensional Fund Advisors LP140,274$1 M0.08%<0.01%no changeJul 31, 2026
🇺🇸 Vanguard Total World Stock Index FundThe Vanguard Group, Inc.139,635$1 M0.08%<0.01%+37%Jul 31, 2026
🇺🇸 State Street SPDR S&P International Small Cap ETFSSGA Funds Management, Inc.86,839$0 M0.05%0.06%+1.0%Jun 30, 2026
🇸🇪 Handelsbanken Global Småbolag Index CriteriaHandelsbanken Fonder AB78,600$0 M0.04%0.01%+23%Jun 30, 2026
🇺🇸 iShares Core MSCI Europe ETFBlackRock Fund Advisors109,529$0 M0.06%<0.01%−2.1%Jul 31, 2026
🇺🇸 Dimensional World ex. U.S. Core Equity 2 ETFDimensional Fund Advisors LP100,763$0 M0.06%<0.01%no changeJul 31, 2026
🇺🇸 Fidelity Total International Index FundFidelity Management & Research Company LLC80,033$0 M0.04%<0.01%no changeJul 31, 2026
🇺🇸 Dimensional International Core Equity Market ETFDimensional Fund Advisors LP70,485$0 M0.04%<0.01%−11%Jul 31, 2026
🇺🇸 Vanguard Esg International Stock ETFThe Vanguard Group, Inc.37,348$0 M0.02%<0.01%+44%May 31, 2026
🇺🇸 State Street Global All Cap Equity ex-U.S. Index PortfolioSSGA Funds Management, Inc.36,261$0 M0.02%<0.01%no changeJun 30, 2026
🇺🇸 World ex U.S. Core Equity PortfolioDimensional Fund Advisors LP45,380$0 M0.02%<0.01%no changeJul 31, 2026
🇺🇸 Fidelity SAI International Small Cap Index FundFidelity Management & Research Company LLC39,176$0 M0.02%0.01%−2.7%Jul 31, 2026
🇺🇸 Invesco RAFI Developed Markets ex-U.S. Small-Mid ETFInvesco Capital Management LLC20,572$0 M0.01%0.02%+3.5%Jul 31, 2026
🇺🇸 International Vector Equity PortfolioDimensional Fund Advisors LP16,930$0 M<0.01%<0.01%no changeJul 31, 2026
🇺🇸 State Street SPDR Portfolio MSCI Global Stock Market ETFSSGA Funds Management, Inc.11,018$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 iShares MSCI Europe Small-Cap ETFBlackRock Fund Advisors15,279$0 M<0.01%0.03%−11%Jul 31, 2026
🇺🇸 Dimensional VA International Small PortfolioDimensional Fund Advisors LP15,101$0 M<0.01%0.01%no changeJul 31, 2026
🇺🇸 iShares MSCI World Small-Cap ETFBlackRock Fund Advisors8,434$0 M<0.01%<0.01%−25%May 31, 2026
🇺🇸 International Sustainability Core 1 PortfolioDimensional Fund Advisors LP10,829$0 M<0.01%<0.01%no changeJul 31, 2026
🇺🇸 Brighthouse/Dimensional International Small Company PortfolioBrighthouse Investment Advisers, LLC7,183$0 M<0.01%<0.01%+98%Jun 30, 2026
🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC12,780$0 M—<0.01%+84%May 31, 2026
🇺🇸 State Street SPDR Portfolio Europe ETFSSGA Funds Management, Inc.6,491$0 M<0.01%<0.01%−2.3%Jun 30, 2026
🇺🇸 Dimensional International Sustainability Core 1 ETFDimensional Fund Advisors LP9,212$0 M<0.01%<0.01%no changeJul 31, 2026
🇺🇸 International Small Company TrustJohn Hancock Variable Trust Advisers LLC5,066$0 M<0.01%0.02%+236%Jun 30, 2026
🇺🇸 The Continental Small Company SeriesDimensional Fund Advisors LP6,914$0 M<0.01%<0.01%−97%Jul 31, 2026
🇺🇸 LVIP Dimensional International Core Equity FundLincoln Financial Investments Corporation3,436$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 AZL DFA International Core Equity FundAllianz Investment Management LLC2,062$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 Dimensional International Vector Equity ETFDimensional Fund Advisors LP2,768$0 M<0.01%<0.01%no changeJul 31, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 49 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Ownership and subsidiaries

Source: GLEIF
Evotec SE directly owns 3 registered entities in 3 countries:

Markets and events: Evotec SE#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
63,321
1 days to cover

Fails to deliver

  • : 2,960 shares at $1.37
  • : 700 shares at $1.63
  • : 671 shares at $1.66

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Evotec SE scorecard#

Passes 5 of the 12 checks that could be worked out: strongest in growth (4 of 6), weakest in profitability (0 of 5). Fiscal year 2024; market cap of Aug 1, 2026.

  • Valuationnot known
    • –P/E below its peers' medianThe market cap dates from 2026-08-01, more than 60 days ago.
    • –Price to book below its peers' medianThe market cap dates from 2026-08-01, more than 60 days ago.
    • –Price to sales below its peers' medianThe market cap dates from 2026-08-01, more than 60 days ago.
    • –Free cash flow yield above 5%The market cap dates from 2026-08-01, more than 60 days ago.
    • –Earnings yield above the 10-year Treasury yieldThe market cap dates from 2026-08-01, more than 60 days ago.
    • –The price assumes slower growth than the last three years'The market cap dates from 2026-08-01, more than 60 days ago.
  • Growth4 of 6
    • ✓Revenue grew in the newest year2.1%Revenue up 2.1% in fiscal 2024.
    • ✓Revenue up more than 5% a year over three years5.7%5.7% a year over the three years to fiscal 2024.
    • ✓Faster growth over three years than its peers' median5.7%5.7% a year against Pharmaceutical's median of 2.5% (65 companies).
    • ✗Earnings per share grew in the newest year-1.20 vs -0.51Diluted EPS -1.20 in fiscal 2024 against -0.51 the year before (report's currency).
    • ✗Net income higher than five years earlier-$212 M-$212 M in fiscal 2024 against $43 M in 2019.
    • ✓Revenue rose in at least four of the last five years5 of 5Revenue rose in 5 of the five years to fiscal 2024.
  • Profitability0 of 5
    • ✗Profitable in the newest year-$212 MNet income -$212 M in fiscal 2024.
    • ✗Profitable in each of the last five years2 of 5Profitable in 2 of the five years to fiscal 2024.
    • ✗Operating margin above its peers' median-17.9%-17.9% against Pharmaceutical's median of 1.8% (74 companies).
    • ✗Return on equity above 15%-19.1%-19.1% in fiscal 2024.
    • –Return on invested capital above 10%No return on invested capital on file.
    • ✗Operating margin wider than three years earlier-17.9%-17.9% in fiscal 2024 against 6.6% in 2021.
  • Financial health1 of 1
    • –Short-term assets cover short-term liabilitiesCurrent assets and liabilities are not on file.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✓Cash from operations positive in each of the last three years3 of 3Positive in 3 of the three years to fiscal 2024.
    • –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
  • Shareholder returnsnot known
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • –Share count up no more than 2% in a yearShare counts of two years are not on file.
    • –Dividends and buybacks above 3% of the market valueThe market cap dates from 2026-08-01, more than 60 days ago.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Pharmaceutical, the 10-year Treasury yield of Nov 13, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Financial analysis, 2024#

Worked out from Evotec SE's statements, beside the median of Pharmaceutical.

Evotec SE: main financial ratios in 2024
Ratio2024Median of peers
Operating margin-17.9%1.8%
Net margin-24.6%-1.5%
Return on equity-19.1%-0.9%
Revenue growth, 3 years a year5.7%2.5%
Revenue growth2.1%7.3%
Free cash flow margin-12.5%6.0%

3of 7on the Piotroski tests of financial strength

  • Net loss of $212 million, the 3th loss-making year in a row.
  • Free cash flow was negative: -$107 million.
  • Revenue has grown 5 years in a row.

Evotec SE: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in EUR millions; per-share figures in EUR; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Evotec SE: statements by fiscal year
PeriodTrendFY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020FY 2019to Dec 31, 2019
Income statement
Revenue797781751618501446
Cost of revenue682606577466375314
Gross profit115175174152126133
Research and development516977726458
Selling, general and administrative1881701561057766
Selling and marketing1717139.49.59.1
Operating income−143−4821414963
Interest and finance income——8.32.31.32.2
Interest expense and finance costs——139.38.57.5
Income before tax−194−81−1542372657
Income tax2.13.322212019
Net income including minority interests−196−84−1762166.337
Minority interests' share of net income—————−0.8
Net income attributable to shareholders——−1762166.338
Earnings per share, basic-1.11-0.47-0.991.300.040.25
Earnings per share, diluted-1.11-0.47-0.991.300.040.25
Shares, weighted average (basic)177177177166154150
Balance sheet
Cash and cash equivalents306511415699423277
Short-term investments909330315959—
Receivables11698172r13279—
Inventory3131302614—
Other current assets2333402121—
Current assets6829031,0741,101659—
Property, plant and equipment——650485337239
Right-of-use (leased) assets——168145142—
Goodwill283276275258247256
Other intangible assets2615243198117
Investments in associates2.13.116134030
Non-current assets1,2311,3491,1841,134803—
Total assets1,9132,2522,2572,2351,462—
Accounts payable8613497———
Debt due within a year——1.63615—
Current liabilities345465338325208—
Long-term debt——328326331—
Lease liabilities (non-current)132170162136131—
Non-current liabilities615668732533529—
Retained earnings−672−476−392−216−433—
Shareholders' equity9531,1201,1871,378724—
Total equity9531,1201,1871,378724479
Total liabilities and equity1,9132,2522,2572,2351,462—
Shares outstanding178177177177164—
Cash-flow statement
Depreciation and amortization102938370——
Share-based compensation5.09.69.97.85.33.6
Cash from operating activities1836206r127r4542
Capital expenditure−117−213−181−119−99−31
Intangible assets bought−15−2.7———−0.6
Acquisitions, net of cash acquired—−2.1−21−0.4−11−40
Cash from investing activities−71−13−413r−243r−155−87
Debt issued0.9220—3122292
Debt repaid−129−113−34−16−6.5−70
Shares issued——0.4403250—
Cash from financing activities−16172−58r393r246211
Exchange-rate effect on cash9.90.6−19−0.19.51.1
Report20-F20-F20-F20-F20-F20-F

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Dec 31, 2024. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

What Evotec SE sells: revenue by product line, fiscal 2025#

As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.

Products and services

  • Fee for service and FTE-based research services$691 M78%
  • Licences$138 M16%
  • Material re-charges to customers$36 M4.0%
  • Milestone fees$11 M1.2%
  • Other fees$0 M0.0%

Business segments

  • Discovery & Preclinical Development$597 M67%
  • Just - Evotec Biologics$293 M33%

Countries and regions

Source: SEC annual report (XBRL data) · as of Dec 31, 2025

Where Evotec SE operates: 6 countries#

Countries where the company has its headquarters, an office, subsidiaries, a branch or reported revenue. 4 subsidiaries on file.

Evotec SE: countries of operation
CountryPresenceRevenue there
🇩🇪 GermanyHeadquarters2 offices1 subsidiary$29 M3.2%
🇮🇹 Italy1 subsidiary—
🇺🇸 USA$487 M55%
🇨🇭 Switzerland$182 M21%
🇬🇧 UK1 subsidiary$70 M7.8%
🇫🇷 France1 subsidiary$22 M2.5%

Source: GLEIF legal-entity register, SEC Exhibit 21 and annual reports, office addresses on file. A country without subsidiaries or offices on record is not listed even if the company sells there. How presence is decided

Discuss Evotec SE#

1 automatic updates and 0 member comments. Sign in to comment and react.

  • Mutual funds: 49 funds hold $78 millionautomatic update · Jul 31, 2026

    49 mutual funds in 2 countries hold shares of Evotec SE worth $78 million, about 8.8% of the company (funds' newest reports, up to 31 July 2026). Since their previous reports 17 funds added shares and 12 sold; on balance they sold $4 million. Share splits are not counted as trading.

How Evotec SE compares in Pharmaceutical

  • Market cap$720 M · higher than 43% of 393
  • Revenue$862 M · higher than 61% of 324
  • Net margin-24.6% · higher than 13% of 313
  • Revenue growth2.1% · higher than 36% of 107
  • Price / sales0.8× · lower than 89% of 219
  • Price / book0.7× · lower than 91% of 207
  • FCF yield-14.9% · higher than 21% of 69

Peer comparison · Pharmaceutical

CompanyMarket capP/ENet marginRev. growth
Evotec SE🇩🇪$720 M—-24.6%+2.1%
Eli Lilly and Company🇺🇸$1.20 T43.4×31.9%+44.7%
Johnson & Johnson🇺🇸$652.5 B40.5×16.2%+6.0%
AbbVie Inc.🇺🇸$514.0 B49.7×15.7%+8.6%
Roche Holding AG🇨🇭$370.3 B29.1×19.0%—
Merck & Co., Inc.🇺🇸$359.8 B146.7×3.6%+1.3%
Novartis AG🇨🇭$286.8 B20.5×24.7%—
Amgen Inc.🇺🇸$249.2 B26.5×24.1%+9.9%
AstraZeneca PLC🇬🇧$242.6 B23.7×17.4%+8.6%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Aug 1, 2026
Annual results:
For year ending December-2024
Balance sheet:
As of December-2024
Employees:
As on 2022
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, value.today research, Wikimedia Commons, GLEIF register; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Evotec SE? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Evotec SE's ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Evotec SE? Suggest a correction